

Engagement Report for Specialised Commissioning Policies

Unique Reference Number and NICE ID	1735 ID007
Policy Title	Selexipag for treating pulmonary arterial hypertension
Accountable Commissioner	Ursula Peaple
Clinical Lead	Gerry Coghlan
Clinical Reference Group	Internal Medicine
Which stakeholders were contacted to be involved in policy development?	Internal Medicine CRG and registered stakeholders Pulmonary Hypertension Association UK
Identify the relevant Royal College or Professional Society to the policy and indicate how they have been involved	
Which stakeholders have actually been involved?	Internal Medicine CRG and registered stakeholders Pulmonary Hypertension Association UK
Explain reason if there is any difference from previous question	Not applicable
Identify any	None, the main patient and carer representative organisation

particular stakeholder organisations that may be key to the policy development that you have approached that have yet to be engaged. Indicate why?	(Pulmonary Hypertension Association UK was involved throughout the development of the draft policy proposition)
How have stakeholders been involved? What engagement methods have been used?	Policy working group meeting and subsequent contact for policy development Stakeholder engagement process. 14 day email engagement exercise with registered stakeholders
What has happened or changed as a result of their input?	Comments have been reviewed by policy working group and amendments made to documents where appropriate following consideration by the Policy Working Group. Changes included: <ul style="list-style-type: none"> • A further simplification of the plain language summary • Updates to the described administration method of prostanoids (to explain that the injectable treatments are given via continuous infusion, and to remove the reference for inhaled prostanoids to a specific nebuliser which will shortly be removed from the market) • Updated the criteria for commissioning to say selexipag would be commissioned “as an option” • Updated the stopping criteria to remove reference to a specific prostanoid • Updated the treatment pathway to clarify that the commissioning of selexipag does not influence the existing commissioning criteria in England’s Commissioning Policy: Targeted Therapies for use in Pulmonary Hypertension in Adults. 2015 and Riociguat for Pulmonary Arterial Hypertension
How are stakeholders being kept informed of progress with policy development as a result of their input?	Stakeholders will be kept informed of the policy’s progress through NHS England’s consultation portal website
What level of wider public	Not all stakeholders made a recommendation. Those that did selected:

consultation is recommended by the CRG for the NPOC Board to agree as a result of stakeholder involvement?	1 - changes that could reasonably be expected to be broadly supported by stakeholders - up to 6 week consultation
---	---

Draft for public consultation